BRPI0411057A - análogos de prostaglandina e de piperidinila - Google Patents

análogos de prostaglandina e de piperidinila

Info

Publication number
BRPI0411057A
BRPI0411057A BRPI0411057-9A BRPI0411057A BRPI0411057A BR PI0411057 A BRPI0411057 A BR PI0411057A BR PI0411057 A BRPI0411057 A BR PI0411057A BR PI0411057 A BRPI0411057 A BR PI0411057A
Authority
BR
Brazil
Prior art keywords
formula
piperidinyl
prostaglandin
analogs
glaucoma
Prior art date
Application number
BRPI0411057-9A
Other languages
English (en)
Inventor
David W Old
Danny T Dinh
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/456,275 external-priority patent/US6747037B1/en
Priority claimed from US10/763,702 external-priority patent/US6977260B2/en
Priority claimed from US10/861,957 external-priority patent/US7179820B2/en
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0411057A publication Critical patent/BRPI0411057A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"ANáLOGOS DE PROSTAGLANDINA E DE PIPERIDINILA". A presente invenção fornece método de tratamento de hipertensão ocular ou glaucoma o qual compreende administrar a um animal tendo hipertensão ocular ou glaucoma quantidade terapeuticamente eficaz de um composto representado pela fórmula geral (I); na qual X, Y, Z, D e R¬ 3¬ são tais como definidos na especificação. Também são descritos compostos compreendendo a fórmula (II) ou um sal farmaceuticamente aceitável ou uma pró-droga destes; onde A, X, J, e R¬ 3¬ são tais como definidos na especificação. Também são descritos compostos tendo uma cadeia <244> e uma <sym> compreendendo a fórmula (III) ou fórmula (IV) ou derivados destes, tais como definidos na especificação ou sais ou pró-drogas farmaceuticamente aceitáveis destes.
BRPI0411057-9A 2003-06-06 2004-06-04 análogos de prostaglandina e de piperidinila BRPI0411057A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/456,275 US6747037B1 (en) 2003-06-06 2003-06-06 Piperidinyl prostaglandin E analogs
US10/763,702 US6977260B2 (en) 2004-01-22 2004-01-22 Piperidinyl prostaglandin E analogs
US10/861,957 US7179820B2 (en) 2003-06-06 2004-06-03 Piperidinyl prostaglandin E analogs
PCT/US2004/018228 WO2004108215A1 (en) 2003-06-06 2004-06-04 Piperidinyl prostaglandin e analogs

Publications (1)

Publication Number Publication Date
BRPI0411057A true BRPI0411057A (pt) 2006-07-25

Family

ID=33514689

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411057-9A BRPI0411057A (pt) 2003-06-06 2004-06-04 análogos de prostaglandina e de piperidinila

Country Status (6)

Country Link
EP (1) EP1631355B1 (pt)
JP (1) JP2006527189A (pt)
AU (1) AU2004245122A1 (pt)
BR (1) BRPI0411057A (pt)
CA (1) CA2528179C (pt)
WO (1) WO2004108215A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977260B2 (en) * 2004-01-22 2005-12-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
EP1761495B1 (en) * 2004-06-04 2012-03-21 Allergan, Inc. Piperidinyl prostaglandin analogs as ocular hypotensive agents
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US20110299830A1 (en) 2009-03-16 2011-12-08 Panasonic Corporation Application running device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1176261A (en) * 1976-06-03 1984-10-16 Albert G. Caldwell Hydantoin derivatives
GB1600127A (en) * 1977-03-23 1981-10-14 Wellcome Found Piperazine-dione derivatives
JPS55145669A (en) * 1979-04-28 1980-11-13 Tanabe Seiyaku Co Ltd 8,10-diazaprostanoic acid derivative and its preparation
GB2094743A (en) * 1981-03-12 1982-09-22 Webb John Edmund Richard Mechanical handling apparatus
JPS59144756A (ja) * 1983-04-28 1984-08-18 Tanabe Seiyaku Co Ltd ８−アザプロスタン酸類化合物及びその製法
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
EP1409455B1 (en) * 2001-07-16 2006-01-04 F. Hoffmann-La Roche Ag Prostaglandin analogues-as ep4 receptor agonists
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
JP2006515015A (ja) * 2003-01-10 2006-05-18 エフ．ホフマン−ラ　ロシュ　アーゲー プロスタグランジンアゴニストとしての２−ピペリドン誘導体

Also Published As

Publication number Publication date
JP2006527189A (ja) 2006-11-30
CA2528179C (en) 2013-10-22
AU2004245122A1 (en) 2004-12-16
EP1631355B1 (en) 2014-08-13
CA2528179A1 (en) 2004-12-16
WO2004108215A1 (en) 2004-12-16
EP1631355A1 (en) 2006-03-08

Similar Documents

Publication Publication Date Title
CY1111951T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
CY1113138T1 (el) Παραγωγα 10,10-διαλκυλ προστανοϊκου οξεος ως παραγοντες για μειωση ενδο-οφθαλμικης πιεσης
WO2001028996A3 (en) Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases
EA200501098A1 (ru) Антибактериальные агенты
EA200500846A1 (ru) Замещенные арилтиомочевины и родственные соединения; ингибиторы вирусной репликации
EA200500814A1 (ru) Производные пирролопиримидина
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
NO20052907D0 (no) Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
ATE342266T1 (de) 1-methylcarbapenemderivate
BRPI0411057A (pt) análogos de prostaglandina e de piperidinila
EA200300272A1 (ru) Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их
BRPI0417300A (pt) métodos para a preparação de compostos de tiazolpirimidina
NO20053997D0 (no) Oligosaccharidderivat
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат
BR0214293A (pt) Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo
MY136065A (en) Prodrugs to nmda receptor ligands
BRPI0410926A (pt) análogos de 3-oxa-8-azaprostaglandinas como agentes para reduzir a pressão intraocular
PL1761495T3 (pl) Analogi piperydynylo prostaglandyny jako hipotensyjne środki oczne
BR0315293A (pt) Derivados de lactona para o tratamento de hiperparatireoidismo
EA200600373A1 (ru) Производные 8-хлор-2,3-бензодиазепина

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 12A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/445 (2006.01), A61P 27/06 (2006.01), C07D